BREAKING NEWS: Moderna’s COVID-19 vaccine protects 90% against infections six months after the final dose
- New data from the Phase III clinical trial showed that Moderna was 90% effective at preventing COVID-19 infection six months after the second dose
- The shot was also more than 95% in preventing serious illness six months later
- This brings Moderna one step closer to filing a full approval application with the FDA after it was approved for emergency use in 2020
According to Moderna Inc, six months after the second dose, the vaccine is more than 90 percent effective against COVID-19.
In updated data from its Phase III clinical trial published Tuesday, the company also said its burst is more than 95 percent effective against serious illness 24 weeks after receiving the final dose.
The new data brings Moderna closer to filing full approval with the US Food and Drug Administration (FDA).
The vaccine was approved for emergency use in people aged 18 and over in December 2020, but with only two months of safety data.
New data from the Phase III clinical trial showed that Moderna was 90% effective at preventing COVID-19 infection six months after the second dose. Image: A vial with the COVID-19 vaccine from Moderna, April 7th
This is breaking news and will be updated.